Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 128 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Atomoxetine Hydrochloride Clear all
Recruiting Phase 2 Interventional

Atomoxetine in Melanocortin Obesity Syndrome

NCT06899178
View directory record Official record
Conditions
Melanocortin Obesity Syndrome, MCOS
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
New York, New York • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 4 Interventional

Atomoxetine Pilot Study in Preschool Children With ADHD

NCT00517647
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
ATMX
Drug
Lead sponsor
University of Arizona
Other
Eligibility
3 Years to 5 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Atomoxetine and Oxybutynin in Obstructive Sleep Apnea

NCT02908529
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
Combination product of Atomoxetine and Oxybutynin, Placebo, 2 tablets
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

Cognitive Effects of Atomoxetine in Humans: Genetic Moderators

NCT01498549
View directory record Official record
Conditions
Addiction
Interventions
Atomoxetine, Sugar Pill
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 2 Interventional

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00429091
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder, ADHD
Interventions
ABT-894, atomoxetine, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
22
States / cities
San Francisco, California • Wildomar, California • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 4 Interventional

Concerta Treatment in Adults With ADHD NOS

NCT00181740
View directory record Official record
Conditions
ADHD NOS
Interventions
atomoxetine (Strattera)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2010 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 2 Interventional

Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar

NCT00174226
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Buspirone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2008 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 3 Interventional

ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD

NCT00557960
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Mixed salts of a single-entity amphetamine, Atomoxetine hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
19 Years to 25 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 4 Interventional

A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia

NCT00222794
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Atomoxetine (Strattera)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 1 Interventional

Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD

NCT00417794
View directory record Official record
Conditions
Fetal Alcohol Syndrome, Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD)
Interventions
Strattera, Placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
4 Years to 11 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 2 Interventional

Study That Tests AD109 in Patients Taking GLP-1 Drugs

NCT06400615
View directory record Official record
Conditions
OSA
Interventions
AD109
Drug
Lead sponsor
Apnimed
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Anniston, Alabama • Jacksonville, Florida • Monroe, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)

NCT01738191
View directory record Official record
Conditions
Parkinson's Disease, Cognitive Impairment
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
35 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 4 Interventional Results available

Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children

NCT00254462
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Placebo, Parent Training
Drug · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
5 Years to 6 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Omaha, Nebraska • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 2 Interventional

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

NCT00142961
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Marijuana Abuse
Interventions
Atomoxetine, placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
14 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)

NCT00702364
View directory record Official record
Conditions
Traumatic Brain INjury
Interventions
atomoxetine, placebo
Drug
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 4 Interventional Results available

Interventions for Children With Attention and Reading Disorders

NCT01133847
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Reading Disabilities
Interventions
Methylphenidate, Intensive reading instruction, Parent Training, Mixed Salt Amphetamine, Atomoxetine, Guanfacine
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 12 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea

NCT05944965
View directory record Official record
Conditions
OSA
Interventions
Atomoxetine 80 mg plus Oxybutynin 5 mg, Atomoxetine 80 MG, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 2, 2026, 4:10 AM EDT
Not listed Phase 4 Interventional

Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents

NCT00252278
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD), Insomnia
Interventions
atomoxetine
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 7, 2006 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 4 Interventional

Evaluation of Continuous Symptom Treatment of ADHD

NCT00486122
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine Hydrochloride, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 12 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 13, 2007 · Synced Oct 2, 2026, 4:10 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Atomoxetine and Executive Function in PTSD

NCT06573970
View directory record Official record
Conditions
Posttraumatic Stress Disorder With Attention Defic
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea

NCT07577661
View directory record Official record
Conditions
Obstructive Sleep Apnea, Sleep-disordered Breathing
Interventions
Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, Placebo; placebo comparator condition
Other · Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 4 Interventional Results available

Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children

NCT00183391
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Methylphenidate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years to 17 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

Medications for Obstructive Sleep Apnea In Children With Down Syndrome

NCT04115878
View directory record Official record
Conditions
Obstructive Sleep Apnea, Down Syndrome
Interventions
Atomoxetine and oxybutynin (ato-oxy)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
6 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 2, 2026, 4:10 AM EDT